These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24198241)

  • 1. The ATP-competitive mTOR inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells.
    Hayman TJ; Wahba A; Rath BH; Bae H; Kramp T; Shankavaram UT; Camphausen K; Tofilon PJ
    Clin Cancer Res; 2014 Jan; 20(1):110-9. PubMed ID: 24198241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel mTORC1/2 dual inhibitor INK128 enhances radiosensitivity of breast cancer cell line MCF-7.
    Liu ZG; Tang J; Chen Z; Zhang H; Wang H; Yang J; Zhang H
    Int J Oncol; 2016 Sep; 49(3):1039-45. PubMed ID: 27574017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.
    Kahn J; Hayman TJ; Jamal M; Rath BH; Kramp T; Camphausen K; Tofilon PJ
    Neuro Oncol; 2014 Jan; 16(1):29-37. PubMed ID: 24311635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.
    Leiker AJ; DeGraff W; Choudhuri R; Sowers AL; Thetford A; Cook JA; Van Waes C; Mitchell JB
    Clin Cancer Res; 2015 Jun; 21(12):2792-801. PubMed ID: 25724523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling.
    Zhang H; Dou J; Yu Y; Zhao Y; Fan Y; Cheng J; Xu X; Liu W; Guan S; Chen Z; shi Y; Patel R; Vasudevan SA; Zage PE; Zhang H; Nuchtern JG; Kim ES; Fu S; Yang J
    Apoptosis; 2015 Jan; 20(1):50-62. PubMed ID: 25425103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma.
    Mazan-Mamczarz K; Peroutka RJ; Steinhardt JJ; Gidoni M; Zhang Y; Lehrmann E; Landon AL; Dai B; Houng S; Muniandy PA; Efroni S; Becker KG; Gartenhaus RB
    Cell Commun Signal; 2015 Mar; 13():15. PubMed ID: 25849580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma.
    Miyahara H; Yadavilli S; Natsumeda M; Rubens JA; Rodgers L; Kambhampati M; Taylor IC; Kaur H; Asnaghi L; Eberhart CG; Warren KE; Nazarian J; Raabe EH
    Cancer Lett; 2017 Aug; 400():110-116. PubMed ID: 28450157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells.
    Raghavan P; Tumati V; Yu L; Chan N; Tomimatsu N; Burma S; Bristow RG; Saha D
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e507-14. PubMed ID: 22795803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the Translation Initiation Factor eIF4A Enhances Tumor Cell Radiosensitivity.
    Lehman SL; Wechsler T; Schwartz K; Brown LE; Porco JA; Devine WG; Pelletier J; Shankavaram UT; Camphausen K; Tofilon PJ
    Mol Cancer Ther; 2022 Sep; 21(9):1406-1414. PubMed ID: 35732578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer.
    Chen YH; Wei MF; Wang CW; Lee HW; Pan SL; Gao M; Kuo SH; Cheng AL; Teng CM
    Cancer Lett; 2015 Feb; 357(2):582-90. PubMed ID: 25497009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competitive but Not Allosteric mTOR Kinase Inhibition Enhances Tumor Cell Radiosensitivity.
    Hayman TJ; Kramp T; Kahn J; Jamal M; Camphausen K; Tofilon PJ
    Transl Oncol; 2013 Jun; 6(3):355-62. PubMed ID: 23730416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR inhibitor INK128 attenuates dextran sodium sulfate-induced colitis by promotion of MDSCs on Treg cell expansion.
    Shi G; Li D; Ren J; Li X; Wang T; Dou H; Hou Y
    J Cell Physiol; 2019 Feb; 234(2):1618-1629. PubMed ID: 30132862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
    Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S
    Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown
    Timme CR; Rath BH; O'Neill JW; Camphausen K; Tofilon PJ
    Mol Cancer Ther; 2018 Jun; 17(6):1207-1216. PubMed ID: 29549168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma.
    Liu T; Sun Q; Li Q; Yang H; Zhang Y; Wang R; Lin X; Xiao D; Yuan Y; Chen L; Wang W
    Mol Cancer Ther; 2015 Feb; 14(2):429-39. PubMed ID: 25504751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted inhibition of mammalian target of rapamycin (mTOR) enhances radiosensitivity in pancreatic carcinoma cells.
    Dai ZJ; Gao J; Kang HF; Ma YG; Ma XB; Lu WF; Lin S; Ma HB; Wang XJ; Wu WY
    Drug Des Devel Ther; 2013; 7():149-59. PubMed ID: 23662044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The second-generation mTOR kinase inhibitor INK128 exhibits anti-inflammatory activity in lipopolysaccharide-activated RAW 264.7 cells.
    Pan H; Xu LH; Ouyang DY; Wang Y; Zha QB; Hou XF; He XH
    Inflammation; 2014 Jun; 37(3):756-65. PubMed ID: 24385238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mTOR Kinase Inhibitor INK128 Blunts Migration of Cultured Retinal Pigment Epithelial Cells.
    Calton MA; Vollrath D
    Adv Exp Med Biol; 2016; 854():709-15. PubMed ID: 26427479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting PRMT5 enhances the radiosensitivity of tumor cells grown in vitro and in vivo.
    Degorre C; Lohard S; Bobrek CN; Rawal KN; Kuhn S; Tofilon PJ
    Sci Rep; 2024 Jul; 14(1):17316. PubMed ID: 39068290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice.
    Heredia A; Le N; Gartenhaus RB; Sausville E; Medina-Moreno S; Zapata JC; Davis C; Gallo RC; Redfield RR
    Proc Natl Acad Sci U S A; 2015 Jul; 112(30):9412-7. PubMed ID: 26170311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.